129589-63-5

Upstream product

• 129589-62-4 1-(tert-butoxycarbonylamino)-3,5-difluorobenzene 
• 79-22-1 methyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 455-40-3 3,5-difluorobenzoic acid 
• 372-39-4 3,5-difluoroaniline 
• 773134-11-5 4-bromo-2,6-difluorobenzoic acid methyl ester 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 191478-99-6 methyl 4-amino-2,6-difluorobenzoate 
• 141412-70-6 diethyl N-(2,6-difluoro-4-(N-((3,4-dihydro-2-methyl-4-oxo-3-((pivaloyloxy)methyl)-6-quinazolinyl)methyl)methylamino)benzoyl)-L-glutamate 
• 141412-64-8 diethyl N-(2,6-difluoro-4-(N-((3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-L-glutamate 
• 141412-65-9 diethyl N-(2,6-difluoro-4-(N-((3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)benzoyl)-L-glutamate 
• 141412-79-5 N-(2,6-difluoro-4-{N-[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]prop-2-ynylamino}benzoyl)-L-glutamic acid 
• 141412-75-1 diethyl N-(4-(N-(tert-butyloxycarbonyl)-N-prop-2-ynylamino)-2,6-difluorobenzoyl)-L-glutamate 
• 141412-80-8 N-(2,6-difluoro-4-{N-[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino}benzoyl)-L-glutamic acid 
• 141412-76-2 diethyl N-(4-(N-(tert-butyloxycarbonyl)-N-methylamino)-2,6-difluorobenzoyl)-L-glutamate 
• 141412-56-8 diethyl N-(2,6-difluoro-4-(prop-2-ynylamino)benzoyl)-L-glutamate 
• 141412-57-9 diethyl N-(2,6-difluoro-4-(methylamino)benzoyl)-L-glutamate 
• 141412-71-7 4-(N-(tert-butyloxycarbonyl)-N-prop-2-ynylamino)-2,6-difluorobenzoic acid 
• 141412-72-8 4-(N-(tert-butyloxycarbonyl)-N-methylamino)-2,6-difluorobenzoic acid 
• 141412-54-6 methyl 4-(N-(tert-butyloxycarbonyl)-N-methylamino)-2,6-difluorobenzoate 

Relevant academic research and scientific papers

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Metallation of N-(Pivaloyl)- and N-(tert-Butoxycarbonyl)difluoroanilines: Regiocontrol by Fluorine in the Synthesis of 4-Methoxycarbonyl Derivatives

Methyl 2,6-difluoro-4-(pivaloylamino)benzoate (3) and the corresponding 4-(tert-butoxycarbonylamino)-analogue 6 have been synthesised by reacting the appropriate 3,5-difluoroaniline derivatives with butyllithium followed by methyl chloroformate.N-(tert-Butoxycarbonyl)-2,3-difluoroaniline (9) required the "super-basic" butyllithium/potassium tert-butoxide mixture to convert it into methyl 4-(tert-butoxycarbonylamino)-2,3-difluorobenzoate (14): the 2,5-difluoro-analogue was formed in a similar manner.In all cases the regiocontrol of metallation was directed by fluorine rather than by the amide substituent.